CytoSorbents Shares Are Trading Higher On Launch Of Trial On Ticagrelor Removal During Cardiothoracic Surgery

• CytoSorbents Corporation (NASDAQ: CTSO) receives full FDA approval to conduct the STAR-T trial in the U.S. to support regulatory clearance of DrugSorb Antithrombotic Removal (ATR) system for intraoperative ticagrelor removal during cardiothoracic surgery.

• This study is being performed under the previously announced FDA Breakthrough Designation received in April 2020.

• STAR-T will enroll up to 120 patients, and enrollment is expected to begin soon.

• The study's primary endpoint will evaluate whether the use of DrugSorb-ATR with the standard of care reduces the risk of perioperative bleeding complications compared to standard of care alone.

• The trial will also evaluate reductions in ticagrelor blood levels and additional outcomes to capture the full potential clinical and cost-economic benefits of DrugSorb-ATR.

• AstraZeneca Plc's (NASDAQ: AZN) Ticagrelor is frequently preferred as first-line therapy in patients with the acute coronary syndrome in preparation for percutaneous coronary intervention (PCI) and stent placement.

• Price Action: CTSO shares are up 12.5% at $8.27 during the premarket session on the last check Tuesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Moderna's COVID-19 Vaccine Produced Neutralizing Titers Against All Variants Tested

• India Made AstraZeneca's COVID-19 Vaccine Not Eligible For EU Travel, Seeks Resolution: Reuters

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.